Ffc-ac-eit

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Human trial2

Outcomes

Physical activity

upin humans1

1 study

Ffc-ac-eit increases physical activity in humans (β = 3.07, 95% CI [1.87, 4.28], p < 0.001).
“physical activity (β = 3.07, 95% CI [1.87, 4.28], p < 0.001) in the FFC-AC-EIT arm”
Human trialhospitalized patients living with dementiaone month post-dischargen = 455
The Impact of FFC-AC-EIT Upon Patient Outcomes
GSA 2025 abstract31 Dec 2025

Physical function

upin humans1

1 study

Ffc-ac-eit improves physical function in humans (β = 5.55, 95% CI [0.36, 10.75], p = 0.036).
“At one month post-discharge there was a significant improvement in function (β = 5.55, 95% CI [0.36, 10.75], p = 0.036)”
Human trialhospitalized patients living with dementiaone month post-dischargen = 455
The Impact of FFC-AC-EIT Upon Patient Outcomes
GSA 2025 abstract31 Dec 2025

Pain

downin humans1

1 study

Ffc-ac-eit decreases pain in humans (β = -0.58, 95% CI [-0.89, -0.26], p < 0.001).
“patients in the FFC-AC-EIT group had less increase in pain than those in the Education-only group (β = -0.58, [95% CI] (-0.89, -0.26), p < 0.001)”
Human trialhospitalized patients living with dementiaat dischargen = 455
The Impact of FFC-AC-EIT Upon Patient Outcomes
GSA 2025 abstract31 Dec 2025